As one of the first hospitals to enter the Boao Lecheng International Medical Tourism Zone in Hainan, the Boao International Hospital of Jimin Health, relying on the policy advantage of “early and pilot implementation” of the zone, has focused its R&D efforts on two major R&D pipelines of adipose-derived mesenchymal stem cells and dendritic cells in the field of cellular therapeutic drugs. Tian Yunfei, director and president of Jimin Health, recently said in an interview with China Securities Journal, “Based on the long-term optimism for the development prospect of cell therapy drugs, Jimin Health will focus on the research and development of Boao International Hospital’s cell therapy drug pipeline in the future.” Joining hands with stem cell experts JiminHealth’s 2024 semi-annual report disclosed the appointment of Jonathan Robert Lakey as the chief scientist of the International Regenerative Medicine Research Center of Boao International Hospital, a controlling subsidiary, and that the ...
1. The more you open, the more you lose In the past few years, drug stores have sprung up all over the country. Whether it is a first-tier city or a small county town, you can see a drug store almost every 50 meters, and there are at least three drug stores at the entrance of a community. The “proliferation” of drug stores has exceeded many people’s imagination. By the end of 2023, there will be nearly 700,000 retail pharmacies in my country, which is more than 100,000 more than the milk tea shops that are everywhere on the streets. In 2012, there were only 440,000 drug stores in my country. In 12 years, the number of drug stores has increased by nearly 50%. Although milk tea shops and snack shops have sprung up in the streets and alleys, they are nothing compared to the expansion speed of chain drug ...
1. Cycles exist objectively, but they are not impossible to cross In recent years, the concept we first used was the “new normal”. The term “new normal” actually lowers social expectations in advance. Later, many experts introduced the concept of “cycle” with the intention of incorporating the current economic situation into a historical cycle. Admittedly, economic development has cycles, and even the spread of viruses has cycles. However, “today’s economic and social conditions should mainly be the result of active choices made by decision-makers. Cyclical factors have an effect but are not decisive, or the adjustment of development direction “encounters” cyclical factors”-excerpted from Du Chen’s “Our Times and Us in the Times”. 2. The current difficulties may only be the initial stage The “new cycle” has just begun, and we must be prepared for long-term hard work. Combining data from the National Bureau of Statistics, Minnet, IQVIA, etc., the average ...
Organiser: Easy Fairs Time: April 21 – 23, 2025 Address: Palais des expositions Pins Maritimes, Algiers 16000, Algeria Exhibition hall: Safex Expo Center Product range: Medical Products Zone: Medical diagnostic equipment & supplies, electronic medical devices & instruments, ambulance equipment, medical reagents & devices, etc. Hospital Supplies Zone: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical tools, medical clothing & bedding, emergency equipment, maternal & infant care equipment, disinfection equipment, etc. Laboratory Equipment Zone: Laboratory instruments & equipment, optical instruments & equipment, image analysis & processing systems, testing instruments & devices, laboratory renovation & upgradation technologies, consumables, and related software, etc. Pharmaceuticals Zone: Various novel drugs, traditional Chinese medicines, western medicines, traditional medicines, herbal medicines, Chinese medicinal health products, nutritional foods, etc. Pharmaceutical Machinery Zone: Pharmaceutical production equipment & technology, pharmaceutical packaging machinery, pharmaceutical packaging materials, production, cleaning, disinfection, and configuration systems for pharmaceuticals. About Maghreb Pharma Expo: The Maghreb ...
On August 28, Buchang Pharma (603858) released its 2024 semi-annual report. During the report period, the company realized operating income of 5.432 billion yuan; realized attributable net profit of 231 million yuan; net cash flow from operating activities was 497 million yuan, an increase of 85.62%, the company’s cash reserves are more adequate. In the context of general industry pressure, Buchang Pharma still shows the strong operating resilience of leading enterprises. During the reporting period, the company actively carried out research and development of multiple types of drugs and gradually perfected the big health industry. Since its establishment, Buchang Pharma has become an important force in promoting local economic development. As of July 2024, Buchang Pharma has accumulated more than 30 billion yuan in national tax payments, making significant contributions to the sustainable and sound development of the local economy. According to statistics, since the listing of eight years, Buchang ...
Nanjing Hengsheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Nanjing Hengsheng”), a subsidiary of Jimin Trustworthy Group, received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration (NMPA), approving the company’s ropinirole hydrochloride sustained-release tablets (specification: 2mg) for sale. This variety is the first generic drug of ropinirole hydrochloride sustained-release tablets approved for sale in China. It is mainly used to treat patients with Parkinson’s disease in the early, middle and late stages and non-motor symptoms. It is developed by the Innovative Technology Drug Research Institute under Jimin Trustworthy Group and Nanjing Hengsheng is in production. Parkinson’s disease is a common degenerative disease of the elderly nervous system. Symptoms include resting tremor, muscle rigidity, bradykinesia, cognitive impairment, etc. The condition worsens over time, causing great burdens on patients’ families and society. Ropinirole hydrochloride is a new dopamine receptor agonist that can enter the central nervous system ...
On the evening of August 29, Tonghua Jinma announced that the company recently received the State Drug Administration issued a listing application for succinium octahydroaminoacridine tablets “Notice of Acceptance”, the oral drug for light, moderate Alzheimer’s disease (Alzheimer’s disease, AD) treatment. On the same day, Tonghua Jinma plate rushed to a halt, closing up 9.98%, closing price of 14.54 yuan / share. Alzheimer’s disease as one of the most common neurodegenerative diseases, the number of its patients with the aging trend of the population and rising. According to the introduction, Succinum Octahydroaminoacridine Tablets is a new, potent, clear mechanism of action of cholinesterase inhibitors, is a new chemical 1 class of drugs with complete independent intellectual property rights, new chemical molecular structure, domestic and foreign have not been marketed. The results of the main pharmacodynamic study show that the drug exhibits strong inhibition of both acetylcholinesterase and butyrylcholinesterase, and by ...
Recently, according to the Financial Times, Siemens Healthineers plans to acquire the diagnostic business of Advanced Accelerator Applications (AAA), a subsidiary of Novartis, for 200 million euros (approximately 1.593 billion yuan). AAA specializes in producing radioactive nuclide drugs, also known as nuclear drugs, for molecular imaging equipment PET (positron emission tomography). The transaction is expected to be completed in the fourth quarter. Expand business territory AAA was spun off from the European Organization for Nuclear Research (CERN) in 2002 and is an innovative radiopharmaceutical company focused on targeted radioligand therapy, precise radioligand imaging, and molecular imaging product development. Its main focus is on the development, production, and commercial application of Molecular Nuclear Medicine (MNM) products. On October 30, 2017, Novartis acquired the company for $3.9 billion to strengthen its radiopharmaceutical business capabilities, making AAA a subsidiary of Novartis. After years of development, AAA has built a pipeline covering various diagnostic ...
Drugdu.com expert’s response: Radioactive Drug Conjugates (RDCs) represent a novel class of therapeutic agents that combine the strengths of precise targeting and potent killing capabilities. By linking radioactive nuclides to ligands (such as antibodies, peptides, small molecules, etc.) through linkers and chelators, RDCs achieve precise localization and effective eradication of target cells. Below, I will elaborate on RDCs from four aspects: definition and structure, advantages and applications, classification, as well as challenges and prospects. I. Definition and Structure Definition: RDCs are drug formulations that integrate radioactive nuclides with targeting molecules (ligands) through linker arms (connectors), aimed at delivering precise strikes against tumor or other disease targets. Structure: RDC drugs consist primarily of targeting ligands, linker arms, chelators, and nuclide conjugates. The targeting ligands recognize and bind to specific target cells or tissues; linker arms connect the targeting ligands to the radioactive nuclides; chelators stabilize the radioactive nuclides, preventing their premature ...
On August 22nd, the National Medical Products Administration announced that it has recently approved the registration applications for two innovative products, the “Transcatheter Aortic Valve System” of Beijing Balance Medical Technology Co., Ltd. (hereinafter referred to as “Balance Medical”). The transcatheter aortic valve system is mainly used to treat aortic valve stenosis, and there are two main treatment options: surgical thoracotomy for valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). TAVR can be roughly divided into ball expanding and self expanding instruments. Compared to SAVR, TAVR has the characteristics of no need for thoracotomy and extracorporeal circulation, minimal trauma, and fast recovery, providing a safer treatment option for high-risk surgical patients. However, in the Chinese market, the penetration rate of TAVR is still relatively low, far below the global level, and a large amount of demand has not been met, with broad prospects. According to Frost&Sullivan data, there were ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.